Enhanced RegIV Expression Predicts the Intrinsic 5-Fluorouracil (5-FU) Resistance in Advanced Gastric Cancer

详细信息    查看全文

• 作者：Li-Sha Ying (1)
  Jiang-Liu Yu (1)
  Xiao-Xiao Lu (1)
  Zhi-Qiang Ling (1)
  
• 关键词：Gastric cancer ; Regenerating islet ; derived family ; member 4 (RegIV) ; 5 ; Fluorouracil ; ATP ; tumor chemosensitivity assay ; Real ; time reverse transcriptase ; PCR
• 刊名：Digestive Diseases and Sciences
• 出版年：2013
• 出版时间：February 2013
• 年：2013
• 卷：58
• 期：2
• 页码：414-422
• 全文大小：418KB
• 参考文献：1. Treatment Architecture China: Gastric Cancer. KantarHealth and Draco Healthcare Consulting, LLC; 2009.
  2. MattsonJack. CancerMPact. The Mattson Jack Group, Inc.; St. Louis, MO. 2009.
  3. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. / Cancer Epidemiol Biomarkers Prev. 2010;19:1893-907. CrossRef
  4. Nomura S, Kaminishi M. Surgical treatment of early gastric cancer. / Dig Surg. 2007;24:96-00. CrossRef
  5. Jain VK, Cunningham D, Chau I. Preoperative and postoperative chemotherapy for gastric cancer. / Surg Oncol Clin N Am. 2012;21:99-12. CrossRef
  6. Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A. Treatment of resectable gastric cancer. / Therap Adv Gastroenterol. 2012;5:49-9. CrossRef
  7. Meyer HJ, Wilke H. Treatment strategies in gastric cancer. / Dtsch Arztebl Int. 2011;108:698-05.
  8. Pasini F, Fraccon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer. / Anticancer Res. 2011;31:3543-554.
  9. Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. / Biochem Pharmacol. 2011;82:201-09. CrossRef
  10. Shekhar MP. Drug resistance: challenges to effective therapy. / Curr Cancer Drug Targets. 2011;11:613-23. CrossRef
  11. Mackenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. / Curr Oncol. 2011;18:e202–e209. CrossRef
  12. Fujii M, Kochi M, Takayama T. Recent advances in chemotherapy for advanced gastric cancer in Japan. / Surg Today. 2010;40:295-00. CrossRef
  13. Ling ZQ, Qi CJ, Lu XX, et al. Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay. / Acta Pharmacol Sin. 2012;33:401-06. CrossRef
  14. Koomen JM, Smalley KS. Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. / Oncotarget. 2011;2:329-35.
  15. Sumantran VN. Cellular chemosensitivity assays: an overview. / Methods Mol Biol. 2011;731:219-36. CrossRef
  16. Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. / Mol Biotechnol. 2007;35:185-97. CrossRef
  17. Kurbacher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. / Methods Mol Med. 2005;110:101-20.
  18. Quintieri L, Fantin M, Vizler C. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. / Adv Exp Med Biol. 2007;593:95-04. CrossRef
  19. Violette S, Festor E, Pandrea-Vasile I, et al. Reg IV a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. / Int J Cancer. 2003;103:185-93. CrossRef
  20. Zhang Y, Lai M, Lv B, et al. Overexpression of Reg IV in colorectal adenoma. / Cancer Lett. 2003;200:69-6. CrossRef
  21. Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S, Dieckgraefe BK. Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. / Gastroenterology. 2006;130:137-49. CrossRef
  22. Li XH, Zheng Y, Zheng HC, et al. REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. / Histol Histopathol. 2010;25:473-84.
  23. Heiskala K, Arola J, Heiskala M, Andersson LC. Expression of Reg IV and Hath1 in neuroendocrine neoplasms. / Histol Histopathol. 2010;25:63-2.
  24. Tamura H, Ohtsuka M, Washiro M, et al. Reg IV expression and clinicopathologic features of gallbladder carcinoma. / Hum Pathol. 2009;40:1686-692. CrossRef
  25. Hayashi T, Matsubara A, Ohara S, et al. Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. / Oncol Rep. 2009;21:95-00.
  26. Sasahira T, Oue N, Kirita T, et al. Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. / Histopathology. 2008;53:667-75. CrossRef
  27. Bishnupuri KS, Luo Q, Korzenik JR, et al. Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. / Cancer Biol Ther. 2006;5:1714-720. CrossRef
  28. Oue N, Mitani Y, Aung PP, et al. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. / J Pathol. 2005;207:185-98. CrossRef
  29. Sentani K, Oue N, Tashiro T, et al. Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. / Am J Surg Pathol. 2008;32:1182-189. CrossRef
  30. Pankova-Kholmyansky I, Arber N. Reg IV can serve for early diagnosis and therapy. / Cancer Biol Ther. 2007;6:123-24. CrossRef
  31. Oue N, Sentani K, Noguchi T, et al. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients. / Int J Cancer. 2009;125:2383-392. CrossRef
  32. Yamagishi H, Fukui H, Sekikawa A, et al. Expression profile of REG family proteins REG Ialpha and REG IV in advanced gastric cancer: comparison with mucin phenotype and prognostic markers. / Mod Pathol. 2009;22:906-13. CrossRef
  33. Gu Z, Rubin MA, Yang Y, et al. Reg IV, a promising marker of hormone refractory metastatic prostate cancer. / Clin Cancer Res. 2005;11:2237-243. CrossRef
  34. Yasui W, Oue N, Sentani K, Sakamoto N, Motoshita J. Transcriptome dissection of gastric cancer: identification of novel diagnostic and therapeutic targets from pathology specimens. / Pathol Int. 2009;59:121-36. CrossRef
  35. Kuniyasu H, Oue N, Sasahira T, et al. Reg IV, enhances peritoneal metastasis in gastric carcinomas. / Cell Prolif. 2009;42:110-21. CrossRef
  36. Mitani Y, Oue N, Matsumura S, et al. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. / Oncogene. 2007;26:4383-393. CrossRef
  37. Vanderlaag K, Wang W, Fayadat-Dilman L, et al. Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer. / Int J Cancer. 2012;130:1251-263. CrossRef
  38. Ling ZQ, Li P, Ge MH, et al. Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancer. / Int J Mol Med. 2011;27:625-35. CrossRef
  39. Bishnupuri KS, Luo Q, Sainathan SK, et al. Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. / Gastroenterology. 2010;138(2):616-26 (626.e1-2).
  40. Glaysher S, Yiannakis D, Gabriel FG, et al. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC). / BMC Cancer. 2009;27:300. CrossRef
  41. Glaysher S, Cree IA. Cell sensitivity assays: the ATP-based tumor chemosensitivity assay. / Methods Mol Biol. 2011;731:247-57. CrossRef
  42. Nakamura R, Saikawa Y, Wada N, et al. Retrospective analysis of treatment for advanced gastric cancer with peritoneal dissemination. / Gan Kagaku Ryoho. 2007;34:1827-831.
  43. Yuan SQ, Zhou ZW, Liang YJ, et al. Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer. / Ai Zheng. 2009;28:337-43.
  
• 作者单位：Li-Sha Ying (1)
  Jiang-Liu Yu (1)
  Xiao-Xiao Lu (1)
  Zhi-Qiang Ling (1)
  
  1. Zhejiang Cancer Research Institute, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, No.38 Guangji Rd., Banshanqiao District, Hangzhou, 310022, People’s Republic of China
  
• ISSN：1573-2568

文摘

Aim RegIV, a member of the Regenerating (REG) gene family, may be a marker for the prediction of resistance to 5-fluorouracil (5-FU)-based chemotherapy. However, the relationship between the intrinsic drug resistance of gastric cancer (GC) cells to 5-FU used alone (single FU) or in multidrug therapeutic regimens (5-FU combinations) and RegIV expression has not been investigated. Methods The patient cohort comprised 45 patients with primary GC. The chemoresistance of GC cells to therapeutic regimens consisting of single 5-FU or FU combinations was investigated using the ATP-tumor chemosensitivity assay. The level of RegIV mRNA transcripts was determined by real-time reverse transcriptase-PCR. RegIV expression was evaluated as a novel predictive biomarker for the intrinsic drug resistance of primary GC cells to single 5-FU or 5-FU combinations. Results Upregulation of RegIV mRNA transcripts was observed in 36 of the 45 tumor specimens and was positively correlated with the invasive depth of the tumor cells (p?=?0.000), the clinical stages (p?=?0.000) and the in vitro intrinsic drug resistance of primary GC cells to 5-FU (p?=?0.000) or 5-FU combinations. Conclusion RegIV mRNA transcript level was strongly associated with the intrinsic resistance of GC cells to single 5-FU or 5-FU combinations, suggesting that RegIV may play an important role in the intrinsic resistance of GC cells to 5-FU and that targeted therapy against the RegIV gene could be applied to overcome 5-FU resistance in the treatment of GC.